Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: Renal outcome of 213 cases

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1593-1598

  Iwakura, Yoshitsugu ^a   Morimoto, Ryo ^a   Kudo, Masataka ^a   Ono, Yoshikiyo ^a   Takase, Kei ^a   Seiji, Kazumasa ^a   Arai, Yoichi ^a   Nakamura, Yasuhiro ^a   Sasano, Hironobu ^a   Ito, Sadayoshi ^a   Satoh, Fumitoshi ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; EPLERENONE; POTASSIUM; SPIRONOLACTONE;

ADRENALECTOMY; ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOKALEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; UNIVERSITY HOSPITAL; URINARY EXCRETION;

ADRENALECTOMY; ADULT; AGED; BLOOD PRESSURE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84899940421     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2180     Document Type: Article

References (19)

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with prima ry aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
2. Born-Frontsberg E, Reincke M, Rump LC, et al; Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities o f hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009;94:1125-1130.
3. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
4. Rossi GP, Bernin i G, Desideri G, et al; PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238.
5. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
6. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005; 16:1320-1325.
7. Reincke M, Rump LC, Quinkler M, et al; Participants of German Conn's Registry. Risk factors associated with a low glomerular filtration rate in primar y aldosteronism. J Clin Endocrinol Metab. 2009;94:869-875.
8. Funder JW, Carey RM, Fardella C, et al; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronis m: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
9. Nishikawa T, Omura M, Satoh F, et al; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J. 2011;58:711-721.
10. Satoh F, Abe T, Tanemoto M, et al. Localization of aldosteroneproducing adrenocortical adenomas: significance of adrenal venous sampling. Hypertens Res. 2007;30:1083-1095.
11. Sasano H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr J. 1994;41:471-482.
12. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)Hypertens Res. 2006 29(Suppl) S1-S105.
13. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. 2009 Revise d equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53:982-992.
14. Danforth DN Jr., Orlando MM, Bartter FC, Javadpour N. Renal changes in primary aldosteronism. J Urol. 1977;117:140-144.
15. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468-1474.
16. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003;14:2255-2263.
17. Hall JE, Granger JP, Smith MJ Jr., Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone " escape." Hypertension. 1984;6:I183-I192.
18. Perez GO, Lespier L, Jac obi J, et al. Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med. 1977;137:852-855.
19. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy A meta-analysis. Diabetologia. 2009;52: 691-697.